Treatment with denosumab vs oral bisphosphonates was associated with increased risks for MACE and hypocalcemia in dialysis-dependent patients with osteoporosis.

The presence of magnesium disorders is strongly associated with the development of short- and especially long-term hypocalcemia following total thyroidectomy, suggesting an important target for the ...

The US Food and Drug Administration (FDA) issued an alert today that cited preliminary evidence for a "substantial risk" for severe and symptomatic hypocalcemia and serious outcomes related to ...

Calcium is an essential mineral that plays a crucial role in various physiological functions, including bone health, nerve transmission, muscle contraction, blood clotting, and enzyme regulation. But ...

Background A 70-year-old man presented with a smooth lump on his buccal mucosa and right-sided cervical lymphadenopathy. Staging investigations revealed extensive sclerotic bone metastases and the ...

The researchers found that with denosumab vs oral bisphosphonates, the risk for emergently treated hypocalcemia increased with worsening CKD stage. (HealthDay News) — For patients with chronic kidney ...

The FDA said it's looking into the risk of severe hypocalcemia among patients on dialysis receiving denosumab (Prolia), citing the potential for severe outcomes, including hospitalization and death.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The risk for developing AKI and hypocalcemia may be ...

Please provide your email address to receive an email when new articles are posted on . Hypocalcemia risk increased with worsening CKD stages, particularly for patients on dialysis. Emergently treated ...

The patient was the third child of nonconsanguineous parents. The family history was negative for congenital heart defects, hypocalcemia, or other congenital anomalies. During the pregnancy, the ...